BASKING RIDGE, N.J., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a company combining a leading cell therapy service provider with a therapeutics pipeline including a Phase 3 clinical program in immuno-oncology and a portfolio of earlier clinical phase projects in immune modulation and ischemic repair, announces today that the Company’s leadership, experts and related research investigators will present at three conferences in November.
SITC 2015 30th Anniversary Annual Meeting & Associated Programs
• Website: http://www.sitcancer.org/2015/
• Venue: Gaylord National Hotel & Convention Center, National Harbor, Maryland
• Date and Time: Thursday, November 5, 2015, 4:00 PM ET
Session 1
• Presenter: Robert Dillman, MD, Vice President, Oncology
• Poster Topic: Superiority of Dendritic Cell Vaccine vs Tumor Cell Vaccine: Survival by stratification subsets in MACVAC randomized phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Session 2
• Presenter: Gabriel Nistor, MD, Vice President, Research
• Poster Topic: Functional Properties of Patient-Derived Melanoma Cancer Stem Cells
American Heart Association Scientific Sessions 2015
• Website: http://scientificsessions.org
• Venue: Orange County Convention Center, Orlando, Florida
Session 1
• Date and Time: Monday, November 9, 2015, 9:00 AM ET
• Session Moderator: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
• Topic: Biological Therapies in Peripheral Artery Disease: Current Standards and Concepts
Session 2
• Date and Time: Monday, November 9, 2015, 9:24 AM ET
• Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer
• Topic: CD34 Positive Cells in PAD: Current Evidence
Session 3
• Date and Time: Monday, November 9, 2015, 4:15 PM ET
• Presenter: Arshed A. Quyyumi, MD, Professor of Medicine at Emory University, Lead Principal Investigator of PreSERVE-AMI study
• Topic: Infused CD34 Cell Dose, Not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients with Left Ventricular Dysfunction Post STEMI: Results of the PreSERVE-AMI trial
Society for Melanoma Research 2015 Congress
• Website: http://www.melanomacongress.com/
• Venue: San Francisco Marriott Marquis, San Francisco, California
• Date and Time: Wednesday, November 18, 2015, 7:30 PM ET
Session 1
• Presenter: Robert Dillman, MD, Vice President, Oncology
• Poster Topic: Superiority in a Randomized Trial of Patient-Specific Dendritic Cell/Tumor Cell Vaccines vs Tumor Cell Vaccines in Subsets Defined by Disease Stage, Tumor Measurability, and Lactate Dehydrogenase (LDH) level
Session 2 • Presenter: Gabriel Nistor, MD, Vice President, Research
• Poster Topic: Mechanism of Action of CLBS20, A Patient-Specific Immunotherapy Targeting Metastatic Melanoma
About Caladrius Biosciences
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius combines a leading cell therapy service provider with a development pipeline including late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for immunomodulation and ischemic repair. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. For more information, visit www.caladrius.com
Help employers find you! Check out all the jobs and post your resume.
